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Summary.-Diethylnitrosamine (DEN), at a concentration of 100 parts/106 in drinking
water for 14 days, caused the development, by 48 weeks, of very few liver tumours in
5 of 18 (27%) male F-344 rats fed control diet. When the DEN treatment was followed
one week later by continuous feeding of the hypolipidemic hepatic peroxisome pro-
liferator, Wy-14,643, at 0.10,0 dietary level, all of 28 rats (1000o) developed, between
38 and 48 weeks, a significantly higher number of liver tumours. Furthermore,
laparotomy at 22 weeks revealed that several rats fed Wy-14,643 after DEN initiation
had developed visible liver nodules, suggesting that Wy-14,643 also accelerates the
appearance of these tumours. Administration of another peroxisome proliferator,
clofibrate, at 0.5o,' level in the diet after DEN initiation, also caused a substantial
enhancement of liver tumorigenesis. The enhancement of liver-tumour development
by clofibrate, however, was less than that by Wy-14,643. The marked enhancing
effect of Wy-14,643 may be due to its profound hepatomegalic and peroxisome pro-
liferative properties.
CHEMICAL carcinogens, even when
administered at a subcarcinogenic level,
produce an irreversible neoplastic change
in some cells of the target organ which is
referred to as "initiation". Subsequent
exposure to certain non-carcinogenic or
weakly carcinogenic agents leads to ac-
celerated development of tumours, a pro-
cess referred to as "promotion" (Boutwell,
1974; Frei, 1976). This concept of initia-
tion and promotion, was first defined for
skin carcinogenesis and forms the basis of
the "two stage hypothesis" (Berenblum
& Shubik, 1947; Salaman & Roe, 1964).
Interest in recent years has been increas-
ingly focused on the important problem of
identifying factors that modify the "ini-
tiation and promotion" phases of carcino-
genesis in various organs.
It is now clearly established that the
number of tumours in skin or in liver is
increased when the cells are stimulated to
proliferate before the administration ofthe
carcinogen, suggesting that rapidly pro-
liferating cells are more susceptible to the
initiating effect of a carcinogen (Glinos et
al., 1951; Pound & Withers, 1963; Frei &
Harsono, 1967; Hollander & Bentvelzen,
1968; Svoboda & Reddy, 1970; Craddock,
1971; Reddy et al., 1976a; Pound &
McGuire, 1978a). Furthermore, cell pro-
liferation also appears to play animportant
part in the promotion of carcinogenesis,
especially in skin (Boutwell, 1974; Frei,
1976; Yuspa et al., 1976; Slaga et al.,
1976).
Peraino et al. (1971; 1977) reported that
feeding a diet containing phenobarbital
to rats previously fed the hepatocarci-
nogen, 2-aceylaminofluorene for a brief
period, markedly increased the subsequent
incidence of hepatic tumour, suggesting
that the stages of initiation and promo-
tion are also operable in liver tumorigene-
sis. Subsequent work by Weisburger et al.
(1975) confirmed the tumour-promotingJ. K. REDDY AND M. S. RAO
effect ofphenobarbital in rat liver, though
the mechanism of phenobarbital promo-
tion remains unknown. Phenobarbital is a
widely used drug which causes hepato-
megaly, due to increased cell division and
proliferation of smooth endoplasmic retic-
ulum in liver cells, as well as inducing drug-
metabolizing microsomal enzymes (Con-
ney, 1967; Schulte-Hermann, 1974). In
recent years, an increasing array of
natural and synthetic chemicals such as
pesticides, drugs, food additives and other
xenobiotics has been shown to induce
hepatomegaly and enzyme induction simi-
lar to that due to phenobarbital treat-
ment (Barka and Popper, 1967; Shulte-
Herman, 1974). Since these agents are
potential environmental contaminants, it
would be important to assess their role as
promoters of liver carcinogenesis, even
if they are found to be non-carcinogenic.
We have shown that several hypo-
lipidemic agents, when administered to
rats and mice, produce a profound hepato-
megalic effect associated with prolifera-
tion of peroxisomes in liver cells (Reddy
et al., 1974; Reddy & Krishnakantha,
1975). Since these agents are administered
clinically for prolonged periods, for the
control of hyperlipidemia, delineation of
various long-term effects of persistent
peroxisome proliferation and hepato-
megalyappearsnecessary. Long-termtreat-
ment with one of these agents, nafenopin,
a closely related analogue of the hypo-
lipidemic drug clofibrate, caused the
development of hepatocellular carcinomas
in mice and rats (Reddy et al., 1976b;
Reddy & Rao, 1977).
We now report that Wy-14,643 ([4-
chloro-6-(2,3-xylidino)-2 -pyrimidinylthio]
acetic acid), a potent hepatic peroxisome
proliferator (Reddy & Krishnakantha,
1975) when administered to rats after a
14-day initiation with the carcinogen
diethylnitrosamine, enhances the develop-
ment of liver tumours in rats. A compari-
son has also been made with the promoting
effects of clofibrate on liver tumorigenesis
in rats similarly exposed to diethylnitro-
samine.
MATERIALS AND METHODS
Animalsandchemicals.-Inbredmale F-344
rats weighing 135-150 g, obtained from
Charles River, Wilmington, Mass. U.S.A.,
were housed in individual cages. Wy-14,643
([4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio)]
acetic acid) was supplied generously by Dr
R. M. Tomarelli, Wyeth Laboratories, Inc.,
Radnor, Pa. U.S.A. Clofibrate (ethyl-ac-p-
chlorophenoxyisobutyrate) was provided gen-
erously by Ayerst Laboratories Inc., New
York, N.Y., U.S.A. Diethylnitrosamine (N-
nitrosodiethylamine) was obtained from East-
man Kodak Co., Rochester, N.Y. U.S.A.
Diethylnitrosamine administration. - Di-
ethylnitrosamine (DEN) was incorporated
into drinking water freshly each day at a
concentration of 100 parts/106 and given for
14 days. After this initiation period, the DEN
administration was discontinued and the
animals were fed control diet and water ad
libitum, for 7 days. After this recovery period,
the animals were divided into 3 groups to
study the effect of Wy-14,643 and clofibrate
on the post-initiation (promotion) phase of
liver tumorigenesis as described below.
Administration of Wy-14,643 and clofibrate
after DEN initiation.-The three groups of
DEN-initiated rats were treated as follows:
Group 1, of 30 rats, was fed Wy-14,643 at a
dietary concentration of 0.1%; Group 2, of
30 rats, was fed clofibrate at a dietary level of
0.5%, and Group 3, of 20 rats, was fed the
basic diet of Purina Laboratory Chow
(Ralston Purina Company, St Louis, Mo.,
U.S.A.) until the termination of the experi-
ment at after 48 weeks of these dietary
regimes. Animals were observed carefully and
weighed once a week. Laparotomies were per-
formed at 22 weeks to assess the development
of liver tumours. Two animals from each
group were killed at this time for histological
studies. The experiment was terminated at
48 weeks, because of progressive loss of
weight and deaths due to liver tumours oc-
curring in rats fed Wy-14,643 between 38
and 48 weeks. Animals were killed by ether
inhalation. Autopsies were done and liver,
lungs and kidneys were fixed in 10% neutral
buffered formalin. Histological sections of
selected lesions were stained routinely with
hematoxylin and eosin.
RESULTS
All rats survived the 14-day treatment
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withDENindrinkingwater. Laparotomies
performed at 22 weeks revealed the pre-
sence of one or more grossly visible nod-
ules 2-6 mm in diameter in the livers of
-,60% of rats fed Wy-14,643 after DEN
initiation. In contrast, only an occasional
rat fed clofibrate, and none of the rats on
control diet, after DEN initiation, had
grossly visible lesions at 22 weeks. Histo-
logical examination of the livers of rats
killed at this time (2 animals from each
group) showed hyperplastic nodules and
many foci of liver-cell proliferation in
only the Wy-14,643 group (Fig. 1).
Between 38 and 48 weeks, 5/28 rats
fed Wy-14,643 after DEN initiation, died
with liver tumours. As these animals lost
considerable weight, all surviving rats
were killed at the 48th week and examined
for hepatic tumours-. The Table compares
the liver tumour incidence in the 3 groups.
The data indicate that 5/18 rats (27%)
fed control diet after DEN initiation
developed liver tumours. A total of 7
tumours were found in these 5 livers, only
3 of which were 10-15 mm in diameter. In
contrast, all 28 rats (100%) fed 0.1%
Wy-14,643 after DEN initiation, devel-
FIG. 1. Liver from a rat fed 0-1% Wy-14,643 in the diet for 22 weeks after DEN initiation. Hyper-
plastic liver nodule. H. and E. x 100.
TABLE.-Liver-tumourincidenceinF-344maleratsfed Wry-14,643or0.5%clofibrate(CPIB)
for 48 weeksfrom 7 days after the administration ofdiethylnitrosame (DEN). DEN was
added to the drinking water at a concentration of 100 parts/106 during the 14-day initiation
period.
No. with % with
No. of
tumours
No. of
tumours
Treatment after No. of liver liver > 0.5 cm/ >1 cm/
DEN initiation ratst tumours tumours liver§ liver§
Control diet 18 5 27 0-38 0-16
0.1% Wy-14,643 28 28t 100* 9.50* 5.00*
0.5% CPIB 28 25 89* 1-50 0-53
* Significantly different from rats fed control diet as determined by x2 test with 1 degree of
freedom (P<0.001).
t Two of these rats also had renal-cell adenomas measuring about 7 mm in diameter.
t Excluding rats killed at 22 weeks (2 from each group).
§ In relation to the total number of rats.
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FIG. 2. Comparison of 4 randomly selected livers from control and Wy-14,643-fed groups after
DEN initiation and killed at 48 weeks. Note the presence of numerous tumours in Wy-14,643-fed
group.
oped multiple liver tumours, 2-35 mm in
diameter, involving all lobes (Fig. 2).
For convenience, the data in the Table
deal with tumours over 5 mm in diameter.
The number of nodules under 5 mm in
diameter, in the livers of animals fed
Wy-14,643, were too numerous to arrive at
a meaningful estimate. Histologically, all
the tumours were hepatocellular in origin
and those larger than 10 mm in diameter
were hepatocellular carcinomas (Fig. 3).
Two rats fed Wy-14,643 had clear-cell
adenomas of the kidney measuring about
7 mm in diameter. In rats fed clofibrate
after DEN initiation, 25/28 animals (890%/)
showed liver tumours. The overall tumour
incidence in the clofibrate group was
significantly greater than that in the
control group, but was significantly less
than that in the Wy-14,643 group. In
animals fed control diet after DEN ini-
tiation, only 3 hepatocellular carcinomas
were found, but several livers contained
an occasional microscopic focus of altered
liver cells (Fig. 4), suggesting tumour foci,
that were either dormant or proliferating
very slowly.
DISCUSSION
Of several factors that appear to pro-
mote the chemical carcinogen-initiated
development of liver tumours (Glinos
et al., 1951; Hollander & Bentvelzen, 1968;
Svoboda & Reddy, 1970; Pound & Mc-
Guire, 1978a and b; Feinstein et al., 1978),
phenobarbital (Peraino et al., 1971) and
dichlorodiphenyltrichloroethane (DDT)
(Peraino et al., 1975) appear unique in that
they produce hepatomegaly and stimulate
DNA synthesis without causing liver-cell
necrosis. Furthermore, both phenobarbital
and DDT are potent inducers of smooth
endoplasmic reticulum proliferation in
liver cells, which is accompanied by an
increase in liver microsomal enzymes
(Conney, 1967; Schulte-Hermann, 1974).
The results of the present study demon-
strate that prolonged dietary administra-
tion of 2 hepatic peroxisome prolifera-
tors, Wy-14,643 and clofibrate, signifi-
cantly enhance the development of liver
tumoursin ratspreviouslyexposedto DEN
for a brief period. In addition to enhanced
incidence, the number of hepatocellular
tumours that developed in each rat,
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FIG. 3.-Hepatocellular carcinoma from a rat fed Wy-14,643 for 48 weeks after DEN initiation.
Shows trabecular pattern. H. and E. x 200
FiG. 4. Liver of a rat fed control diet for 48 weeks after DEN initiation. Focal proliferations of
liver cells such as these indicate slow or arrested growth of initiated cell(s). H. and E. x 100.
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especially with Wy-14,643 feeding, was
also greatly increased. Continuous feeding
of these peroxisome proliferators, there-
fore, appears to act as a promotor of liver
careinogenesis.
Wy-14,643 and clofibrate are known to
reduce serum lipids, and cause a marked
increase in liver weight in both rats and
mice (Hess et al., 1965; Svoboda et al.,
1967; Reddy & Krishnakantha, 1975).
In addition, they induce the proliferation
of peroxisomes in liver cells, with an
increase in some enzymes associated with
this organelle (Reddy & Krishnakantha,
1975; Moody & Reddy, 1978). These
changes are considered analogous to the
proliferation of smooth endoplasmic retic-
ulum andinduction ofmicrosomal enzymes
in liver by phenobarbital and other
xenobiotics. Because of the long-term
administration of drugs such as these for
the control of hyperlipidemic states in
man, it is essential to investigate various
aspects of persistent hepatomegaly and
peroxisome proliferation.
The mechanism of enhancement of liver
tumorigenesis in animals fed Wy-14,643
or clofibrate, after DEN initiation remains
to be elucidated. All potent peroxisome
proliferators such as Wy-14,643, BR-931
and nafenopin (Reddy et al., 1978b; Moody
et al., 1977) stimulate liver-cell prolifera-
tion during the initial stages of feeding,
as well as causing cellular hypertrophy.
The hepatomegalic as well as mitogenic
effects of clofibrate appear somewhat less
pronounced than with Wy-14,643 (Moody
& Reddy, 1978). The question arises
whether the increased hepatocellular tu-
mour yield in Wy-14,643-fed rats, over the
clofibrate-fed group, reflects the mitogenic
potency ofthis agent. Several studies have
stressed that cell proliferation is important
in the promotion of skin carcinogenesis
(Boutwell, 1974; Frei, 1976) and it is
possible that phenobarbital (Peraino et al.,
1971) DDT (Peraino et al., 1975) carbon
tetrachloride (Pound & McGuire, 1978b)
and now the peroxisome proliferators,
exert their enhancing effect on liver
tumorigenesis by increasing the rate of
liver-cell proliferation. In addition, drugs
such as phenobarbital, DDT, Wy-14,643
and clofibrate increase the membranes in
liver cells, and may influence membrane
functions. The role, if any, of persistent
increase in peroxisomes and/or smooth
endoplasmic reticulum in liver-tumour
promotion needs to be clarified. Further-
more, emerging evidence indicates that
potent peroxisomes proliferators such as
nafenopin, a closely related analogue of
clofibrate, and Wy-14,643, which is struc-
turally unrelated to clofibrate, are hepato-
carcinogenic to rats and mice when
administered for prolonged periods (Reddy
et al., 1976b; Reddy & Rao, 1977; Reddy
et al., 1978a; Reddy, unpublished). Un-
published data also suggest that the drug
clofibrate may be a weak hepatocarcino-
gen. These observations, coupled with the
data presented in this paper on the en-
hancing effect of Wy-14,643 and clofibrate
on liver-tumour development in rats
after DEN initiation, suggest the need for
long-term studies with other hypolipi-
demic peroxisome proliferators to clarify
the role of peroxisomes in hepatocarcino-
genesis and/or in its promotion.
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